Moses Joloba Lutaakome
ID: UNCST-2022-R011558
|
Bacterial and Host Determinants in TB Transmission: Immune Phenotypes Associated with Exposure to High and Low Transmission Strains of MTB - Uganda
REFNo: HS1498ES
The goal of this study is to identify the bacterial and host factors that promote transmission of tuberculosis (TB), a necessary first step towards developing drugs and vaccines that prevent the inter-person spread of Mycobacterium tuberculosis (Mtb). This study has five specific aims:
Aim 1: Determine the extent to which household transmission is responsible for co-prevalent and incident TB cases caused by Mtb strains that are genetically distinct from those isolated from the index cases within the same household.
Aim 2: Investigate the in vitro immune phenotype of transmitted versus not-transmitted Mtb strains in households stratifying for HIV status.
Aim 3: Characterize the innate macrophage response to high and low transmission strains and the T-cell response in persons with known household exposure to high and low transmission isolates and the impact of HIV infection.
Aim 4: Identify the component of Mtb genes that aid in bacterial survival in aerosols.
Aim 5: Investigate the bacterial factors underlying divergence in the host response to high and low transmission isolates.
|
Uganda |
2021-08-24 |
2024-08-24 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Peter Elyanu James
ID: UNCST-2021-R013210
|
CoVPN 3008- UBUNTU Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern. Version 1.0, dated 16 May 2021. DAIDS Document ID # 38838.
REFNo: HS1642ES
Primary Objectives
The primary objectives of this study are to determine the following:
1. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in adults who are at risk of severe COVID-19
2. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
3. To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19
Secondary Objectives
The secondary objectives of this study are to evaluate the following:
1. Durability of VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 through the final study visit (Month 12 post-dose 1) in volunteers with no previous COVID-19
2. VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19
3. VE of COVID-19 mRNA vaccine against SARS-CoV-2 infection defined by nucleocapsid protein seroconversion regardless of symptomology in volunteers with no previous COVID-19
4. VE of COVID-19 mRNA vaccine against asymptomatic SARS-CoV-2 infection defined by nucleocapsid protein seroconversion without prior occurrence of the symptomatic COVID-19 primary endpoint in volunteers with no previous COVID-19
5. Post -vaccination immune response markers as correlates of risk of COVID-19 and as correlates protection against COVID-19
6. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in all participants regardless of baseline SARS-CoV-2 status
Exploratory Objectives
The exploratory objectives of this study are to evaluate the following:
1. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 by baseline HIV infection status in volunteers with no previous COVID-19 and in all volunteers regardless of previous COVID-19 status
2. VE of COVID-19 mRNA vaccine against COVID-19 and against severe COVID-19 by neutralization phenotype and Spike sequence features of acquired SARS-CoV-2 viruses (sieve analysis), including VE against the B.1.351/501Y.V2 variant and VE against all other variants combined in volunteers with no previous COVID-19 and in all volunteers regardless previous COVID-19 status
3. VE of COVID-19 mRNA vaccine against COVID-19 and severe COVID-19 in volunteers with previous COVID-19
4. Relative rate of COVID-19 and severe COVID-19 in placebo recipients with previous COVID-19 compared to vaccine recipients with no previous COVID-19
5. Assess T-cell responses in placebo recipients who develop COVID-19 compared to vaccine recipients who develop symptomatic COVID-19
6. Assess incidence of adverse birth outcomes among pregnant persons enrolled in the trial
|
Uganda |
2021-08-24 |
2024-08-24 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Perez Mujuni Perez Mbiire Batwine
ID:
|
Teachers' welfare, human capital and performance of Government aided primary school in Isingiro District
REFNo: SS964ES
i. To establish the relationship between teachers’ welfare and performance of government aided primary schools in Isingiro District.
ii. To establish the relationship between human capital and performance of government aided primary schools in Isingiro District.
iii. To find out the effect of combining teachers’ welfare and human capital on the performance of government aided primary schools in Isingiro District.
iv. To find out whether monitoring systems mediates teachers’ welfare and the performance of government aided primary schools in Isingiro District.
v. To find out whether monitoring systems mediates human capital and the performance of government aided primary schools in Isingiro District.
|
Uganda |
2021-08-23 |
2024-08-23 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Hasifah Namatovu Kasujja
ID:
|
eHealth Adoption in Uganda. What is the status? eHAU
REFNo: SS945ES
1. To inventory existing eHealth interventions in Uganda to ascertain maturity, failure and successes
2. To study the barriers and facilitators of eHealth adoption in Uganda
3. To develop a framework for successful eHealth adoption
4. To evaluate the framework for utility
|
Uganda |
2021-08-23 |
2024-08-23 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Ronald Kiguba
ID: UNCST-2019-R000844
|
Two-way risk communication mobile application use versus traditional methods of adverse drug reaction reporting in Uganda: a cluster-randomized controlled trial
REFNo: HS1366ES
This study will: i) assess the feasibility of implementing a mobile app for the reporting of ADRs associated with DTG and IPT at selected ART-sites in Uganda; ii) describe the characteristics (causality, seriousness, completeness, unexpectedness, severity, outcome) of the DTG- and IPT-linked ADR-reports submitted to NPC using the mobile app; and, iii) determine if use of the mobile app versus existing methods of ADR-reporting (paper-form and web-form) increases by 25% the number of reported ADRs linked to DTG and IPT use during 2.5 years of follow-up, iv) determine the cost and cost-effectiveness of using the mobile app versus existing methods of ADR-reporting.
|
Uganda |
2021-08-20 |
2024-08-20 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|